Falguni Asrani, MD
Dermatology · New York, NYNPI 1942596465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,284, 4.3 times the $301 reported in 2019.
Across 154 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$668
- Johnson & Johnson$446
- Pfizer$410
- Dermavant Sciences, Inc.$277
- Novartis$238
- Sanofi$212
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,01690%
- Education$32910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $668 |
| Johnson & Johnson | 14 | $446 |
| Pfizer | 21 | $410 |
| Dermavant Sciences, Inc. | 12 | $277 |
| Novartis | 9 | $238 |
| Sanofi | 9 | $212 |
| Incyte Corporation | 8 | $196 |
| Regeneron Healthcare Solutions, Inc. | 7 | $148 |
| Amgen | 4 | $119 |
| Galderma Laboratories, L.p. | 4 | $79 |
| Arcutis Biotherapeutics, Inc. | 3 | $75 |
| Bristol Myers Squibb | 4 | $72 |
| Lilly USA, LLC | 3 | $66 |
| Organon | 2 | $50 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| UCB, Inc. | 2 | $40 |
| Almirall LLC | 2 | $37 |
| Mayne Pharma Commercial LLC | 2 | $32 |
| LEO Pharma Inc. | 1 | $26 |
| VYNE Pharmaceuticals Inc. | 1 | $24 |
| LNHC, Inc | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
How this compares
$3,344 in reported general payments places this provider in the 55th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 11 | $2,539 |
| Clobetasol Propionate | 17 | $1,868 |
| Triamcinolone Acetonide | 19 | $285 |
| Ketoconazole | 16 | $171 |
| Fluconazole | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.